Lymphocyte Activation Gene 3 (LAG-3)

Joel C. Sunshine, Evan Lipson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lymphocyte activation gene 3 (LAG-3, CD223) is a protein expressed on the surface of activated T cells, regulatory T cells (Treg), natural killer (NK) cells, B cells, and plasmacytoid dendritic cells. LAG-3 signaling inhibits T cell activation and enhances regulatory T cell function (Camisaschi et al. 2010; Grosso et al. 2007; Joosten et al. 2007; Park et al. 2012). Like other molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and T cell immunoglobulin mucin-3 (TIM-3), LAG-3 has attracted interest in oncology for its role as a negative regulator of T cell activation - an immunological "checkpoint" - that may play a role in helping tumors evade effective immune surveillance. This chapter will present a brief discussion of the molecular structure and biologic function of LAG-3 as a therapeutic target. The current role of LAG-3 in cancer with attention to pertinent preclinical and clinical data will be described. Finally, the potential impact and future directions of research into the optimal use of LAG-3 as a therapeutic target will be presented.

Original languageEnglish (US)
Title of host publicationCancer Therapeutic Targets
PublisherSpringer New York
Pages375-383
Number of pages9
Volume1-2
ISBN (Electronic)9781441907172
ISBN (Print)9781441907165
DOIs
StatePublished - Jan 1 2017

Keywords

  • Cancer
  • Immunotherapy
  • LAG-3
  • T cell

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Lymphocyte Activation Gene 3 (LAG-3)'. Together they form a unique fingerprint.

  • Cite this

    Sunshine, J. C., & Lipson, E. (2017). Lymphocyte Activation Gene 3 (LAG-3). In Cancer Therapeutic Targets (Vol. 1-2, pp. 375-383). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_136